title: Ultraviolet recall dermatitis reaction with sorafenib.
abstract: OBJECTIVE
  Recall dermatitis is a rare and poorly understood drug-related event. Activated by exposure to sunlight or Ultraviolet (UV), drug-related phototoxic reactions have been reported with conventional chemotherapy agents or antibiotics.
  
  
  METHODS
  Here, we report the first case of acute dermatologic photo-induced recall reaction secondary to sorafenib in a patient with renal cell carcinoma.
  
  
  RESULTS
  Four weeks after stopping sorafenib, a patient with renal cell carcinoma developed an acute erythematous and papulomatous eruption restricted to the hands after prolonged solar exposure. The erythematous region was very well demarcated, mimicking the cutaneous syndrome that the patient had presented at time he was receiving sorafenib.
  
  
  CONCLUSIONS
  The suppression of the phototoxic reaction by corticosteroids strongly suggests that the immune system may have an important function in photo-recall reactions.
authors.affiliation: Department of Radiotherapy, Institut de Cancérologie de la Loire, 108 bis, avenue Albert Raimond, BP 60008, 42271 Saint Priest en Jarez, France. nicolas.magne@icloire.fr
authors.forename: Nicolas
authors.initials: N
authors.lastname: Magné
authors.forename: Cyrus
authors.initials: C
authors.lastname: Chargari
authors.forename: Pierre
authors.initials: P
authors.lastname: Auberdiac
authors.forename: Coralie
authors.initials: C
authors.lastname: Moncharmont
authors.forename: Yacine
authors.initials: Y
authors.lastname: Merrouche
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Spano
mesh_terms: D001557:Benzenesulfonates / Q000009:adverse effects*; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D011855:Radiodermatitis / Q000139:chemically induced*; D000077157:Sorafenib; D014466:Ultraviolet Rays / Q000009:adverse effects*
chemical_list: D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib